AstraZeneca PLC (AZN)vsRepligen Corporation (RGEN)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
RGEN
Repligen Corporation
$122.31
-3.35%
HEALTHCARE · Cap: $6.99B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7818% more annual revenue ($60.44B vs $763.34M). AZN leads profitability with a 17.2% profit margin vs 6.7%. AZN appears more attractively valued with a PEG of 1.39. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
RGEN
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+10.3%
Fair Value
$155.38
Current Price
$122.31
$33.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Earnings expanding 47.9% YoY
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
ROE of 2.4% — below average capital efficiency
6.7% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : RGEN
The strongest argument for RGEN centers on EPS Growth. Revenue growth of 14.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : RGEN
The primary concerns for RGEN are PEG Ratio, Return on Equity, Profit Margin. A P/E of 137.7x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while RGEN is a value play — different risk/reward profiles.
RGEN carries more volatility with a beta of 1.09 — expect wider price swings.
RGEN is growing revenue faster at 14.8% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 49/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Repligen Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?